Skip to main content

IMRAB 3

This page contains information on IMRAB 3 for veterinary use.
The information provided typically includes the following:
  • IMRAB 3 Indications
  • Warnings and cautions for IMRAB 3
  • Direction and dosage information for IMRAB 3

IMRAB 3

This treatment applies to the following species:
Company: Boehringer Ingelheim Animal Health

Rabies Vaccine, Killed Virus

Rabies 3 Year

IMRAB 3 Indications

This product has been shown to be effective for the vaccination of healthy cats, dogs, sheep, cattle, horses, and ferrets 12 weeks of age and older against rabies virus. The duration of immunity is at least 3 years for cats, dogs, and sheep, and at least 1 year for ferrets, cattle, and horses. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

Description

Imrab® 3 contains the same virus strain that is used in the Pasteur Merieux Connaught human vaccine. The virus is grown in a stable cell line, inactivated, and mixed with a safe and potent adjuvant. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible animals.

Directions and dosage: Shake well before use. Aseptically inject 1 mL (1 dose) subcutaneously or intramuscularly into healthy dogs or cats; 2 mL into healthy sheep, cattle, and horses. Inject 1 mL subcutaneously into healthy ferrets. Revaccinate ferrets, cattle, and horses annually; cats, dogs, and sheep 1 year after first vaccination, then every 3 years with a single dose.

Precautions

Store at 2-8°C (35-46°F). Do not freeze. Do not use chemicals to sterilize syringes and needles. Do not mix with other products. Use entire contents when first opened. Contains gentamicin and thimerosal as preservatives. Do not vaccinate food producing animals within 21 days prior to slaughter. This product has not been tested in pregnant animals. A transient local reaction may occur at the injection site following subcutaneous administration. Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection site fibrosarcomas. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine. In case of human exposure, contact a physician.

For use in animals only.

Restricted to use by or under the direction of a veterinarian.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., Athens, GA 30601

Tel: 1 (888) 637-4251

VLN/PCN 124/1905.20

Distributed in Canada by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

Imrab® is a registered trademark in the USA of Boehringer Ingelheim Animal Health USA Inc.

Imrab® is a registered trademark in Canada of Boehringer Ingelheim Animal Health France SCS, used under license.

 

Contains

Prod. No.

 

Dogs, Cats & Ferrets

50 doses - 5 x 10 doses (10 mL)

2310-05

RM949R10

RM532R9

Sheep, Cattle & Horses

25 doses 5 x 5 doses (10 mL)

CPN: 1028340.0

BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
3239 SATELLITE BLVD., DULUTH, GA, 30096
Telephone:   800-325-9167
Fax:   816-236-2717
Website:   www.bi-vetmedica.com
    www.metacam.com
    www.prozinc.us
    www.vetera-vaccines.com
    www.vetmedin-us.com
Email:   info@productionvalues.us
Every effort has been made to ensure the accuracy of the IMRAB 3 information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2022 Animalytix LLC. Updated: 2021-11-29